Aclaris Therapeutics, Inc.
ACRSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ACRS. That does not mean none is planned.
Get an email about ACRS's next catalysts
Track Aclaris Therapeutics (ACRS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 2 past
ACRS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.16 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Active
Common Wart
A-101 Solution
Seborrheic Keratosis
A-101
Common Wart
ATI-1777
Atopic Dermatitis
A-101 Vehicle
Seborrheic Keratosis
A-101 Topical
Dermatosis Papulosa Nigra
A-101 Topical Solution
Common Wart
ATI-50002 topical solution
Vitiligo
ATI-501 (Low dose)
Alopecia
ATI-2138
Atopic Dermatitis
ATI-50002
Androgenetic Alopecia
A-101 Vehicle Solution
Common Wart
A-101 Solution 40
Common Warts
Zumsemetinib
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
ATI-501 (Mid dose)
Alopecia
A-101 (32.5) Topical Solution
Seborrheic Keratosis
A-101 (40) Topical Solution
Seborrheic Keratosis
A-101 Solution 45
Common Warts
ATI-450
Rheumatoid Arthritis
ATI-501 (High dose)
Alopecia
ATI-502
Atopic Dermatitis
ATI-045
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Active | Phase 3 | Common Wart | - | |
A-101 Solution | Phase 3 | Seborrheic Keratosis | - | - |
A-101 | Phase 3 | Common Wart | - | - |
ATI-1777 | Phase 2 | Atopic Dermatitis | - | - |
A-101 Vehicle | Phase 2 | Seborrheic Keratosis | - | - |
A-101 Topical | Phase 2 | Dermatosis Papulosa Nigra | - | - |
A-101 Topical Solution | Phase 2 | Common Wart | - | - |
ATI-50002 topical solution | Phase 2 | Vitiligo | - | - |
ATI-501 (Low dose) | Phase 2 | Alopecia | - | - |
ATI-2138 | Phase 2 | Atopic Dermatitis | - | - |
ATI-50002 | Phase 2 | Androgenetic Alopecia | - | - |
A-101 Vehicle Solution | Phase 2 | Common Wart | - | - |
A-101 Solution 40 | Phase 2 | Common Warts | - | - |
Zumsemetinib | Phase 2 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | - | - |
ATI-501 (Mid dose) | Phase 2 | Alopecia | - | - |
A-101 (32.5) Topical Solution | Phase 2 | Seborrheic Keratosis | - | - |
A-101 (40) Topical Solution | Phase 2 | Seborrheic Keratosis | - | - |
A-101 Solution 45 | Phase 2 | Common Warts | - | - |
ATI-450 | Phase 2 | Rheumatoid Arthritis | - | - |
ATI-501 (High dose) | Phase 2 | Alopecia | - | - |
ATI-502 | Phase 2 | Atopic Dermatitis | - | - |
ATI-045 | Phase 2 | Atopic Dermatitis | - | - |
Atopic Dermatitis
5 drugs in this indication
Common Wart
4 drugs in this indication
Rheumatoid Arthritis
2 drugs in this indication
Seborrheic Keratosis
2 drugs in this indication
Alopecia
2 drugs in this indication
Dermatosis Papulosa Nigra
2 drugs in this indication
Alopecia Universalis (AU)
1 drug in this indication
Vitiligo
1 drug in this indication
Seborrheic Keratosis (SK)
1 drug in this indication
Androgenetic Alopecia
1 drug in this indication
Common Warts
1 drug in this indication
Moderate to Severe Lichen Planus
1 drug in this indication
Hidradenitis Suppurativa
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Aclaris Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 22 drug candidates in Aclaris Therapeutics, Inc.'s (ACRS) pipeline across Phase 3, Phase 2. Its lead program is A-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aclaris Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Aclaris Therapeutics, Inc. (ACRS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACRS biotech catalysts?→
Add ACRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aclaris Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.